| Identification | Back Directory | [Name]
BETi-211 | [CAS]
1995867-02-1 | [Synonyms]
BETi-211
9H-Pyrimido[4,5-b]indol-4-amine, N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethyl-4-isoxazolyl)-6-methoxy-2-(methoxymethyl)- | [Molecular Formula]
C26H29N7O3 | [MOL File]
1995867-02-1.mol | [Molecular Weight]
487.55 |
| Hazard Information | Back Directory | [Description]
BETi-211 is a novel selective BET bromodomain inhibitor. | [Uses]
BETi-211 is an orally active BET inhibitor (Ki: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC50 < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors[1]. | [References]
[1] Bai L, et al. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017 May 1;77(9):2476-2487. DOI:10.1158/0008-5472.CAN-16-2622 |
|
|